A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia

Br J Haematol. 2019 May;185(3):623-627. doi: 10.1111/bjh.15593. Epub 2018 Sep 11.
No abstract available

Keywords: FLT3; acute leukaemia; midostaurin; paediatric; relapsed/refractory.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / metabolism
  • Male
  • Staurosporine / administration & dosage
  • Staurosporine / adverse effects
  • Staurosporine / analogs & derivatives*
  • Survival Rate

Substances

  • Staurosporine
  • midostaurin